Search

EHA Friends' Fund

Together, we can change the lives of many and make greater strides in the treatment of patients with blood disorders.

Read more

Stopping tyrosine kinase inhibitors in a very large cohort of European chronic myeloid leukemia patients: results of the EURO-SKI trial

Tyrosine kinase inhibitors (TKI) have substantially improved survival in patients with chronic myeloid leukemia in chronic phase. However, treatment is in clinical practice considered life-long.

Read more

Publications

Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY
Thomas Chatzikonstantinou; Lydia Scarfò; Georgios Karakatsoulis; Eva Minga; Dimitra Chamou; Gloria Iacoboni; Jana Kotaskova; Christos Demosthenous; Lukas Smolej;…

Read more

Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing

Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.

Read more

EHA supports the proposal for a Regulation on the European Health Data Space (EHDS)

On October 20, the European Hematology Association (EHA) joined a group of 35 stakeholders in welcoming the European Commission’s proposal on the European Health Data Space.

Read more